FDA and EPA Regulatory Actions Draw Scrutiny from Advocacy Groups
What happened
Regulatory actions taken by the FDA and EPA in 2017 drew criticism from advocacy groups. The Natural Resources Defense Council actively challenges and influences FDA regulatory findings and policy decisions regarding chemical safety.
From science20.com
Why it matters
The actions drew scrutiny from groups like the Natural Resources Defense Council, which actively challenges the policies of the EPA and the FDA. Regulatory changes can influence compliance costs for regulated industries and drive pharmaceutical market revenue.
From science20.com
Who's involved
- FDARegulatory agency that formally regulates drug development and market activities
- EPARegulatory agency whose policies are actively challenged by advocacy groups
- Natural Resources Defense CouncilNon-profit advocacy group that actively challenges and opposes EPA and FDA policies
- Donald TrumpPolitician whose administration appointed science advisors to the FDA and EPA
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- EPASpeculative
Regulated industries might see reduced compliance costs following EPA rule changes.
Keep exploring
The entities involved
- FDA
-
EPA
defunct retail company
-
Natural Resources Defense Council
non-profit international environmental advocacy group, with its headquarters in New York City
Related events
- ACP guidance aligns with FDA label updates, prompting the Senate to hold hearings on the changes.
- FDA approval enables commercial opportunity involving CBRE Group.
- Litigation regarding FDA approval process.
- The FDA is facing public scrutiny due to oversight failures, leading to the introduction of new legislation targeting agency shortcomings.